Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.4% - Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price fell 2.4% on Tuesday . The stock traded as low as $7.50 and last traded at $7.76. 8,984,496 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 15,902,586 shares. The stock had previously closed at $7.95.

Analyst Ratings Changes

Separately, Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $9.25.

Recursion Pharmaceuticals Trading Down 5.8 %

The stock has a market cap of $2.93 billion, a P/E ratio of -4.90 and a beta of 0.85. The stock's 50-day moving average is $6.89 and its two-hundred day moving average is $7.03. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's revenue for the quarter was up 147.6% on a year-over-year basis. During the same period last year, the company earned ($0.43) EPS. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 6,000 shares of the stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $6.31, for a total value of $37,860.00. Following the sale, the chief operating officer now owns 521,138 shares of the company's stock, valued at approximately $3,288,380.78. This represents a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total transaction of $76,923.84. Following the transaction, the director now directly owns 7,077,560 shares of the company's stock, valued at approximately $47,561,203.20. This represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 55,341 shares of company stock valued at $393,490 in the last ninety days. Corporate insiders own 15.75% of the company's stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after buying an additional 4,948 shares during the period. JPMorgan Chase & Co. increased its position in Recursion Pharmaceuticals by 6.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company's stock valued at $7,751,000 after purchasing an additional 67,464 shares during the period. Franklin Resources Inc. raised its holdings in shares of Recursion Pharmaceuticals by 58.9% in the 3rd quarter. Franklin Resources Inc. now owns 18,963 shares of the company's stock valued at $127,000 after purchasing an additional 7,027 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter worth approximately $89,000. Finally, Geode Capital Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 13.7% during the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock valued at $35,803,000 after purchasing an additional 656,003 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.